Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure;Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca

Revista Espanola de Cardiologia

Volumn 57, Issue 5, 2004, Pages 447-464

  Tamargo, Juan ^a   López Sendón, José ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Heart failure; Inotropic drugs; Neurohumoral antagonists

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CANDESARTAN; CONIVAPTAN; DARUSENTAN; DOBUTAMINE; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; ETANERCEPT; FASIDOTRIL; IMMUNOGLOBULIN; MOZAVAPTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N [[1 (2 ACETYLTHIO 3 METHYL 1 OXOBUTYLAMINO) 1 CYCLOPENTYL]CARBONYL] O METHYLTYROSINE ETHYL ESTER; NESIRITIDE; OMAPATRILAT; PENTOXIFYLLINE; SETASTINE; TEZOSENTAN; TOLVAPTAN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR; VASOPRESSIN RECEPTOR ANTAGONIST;

CLINICAL TRIAL; DRUG EFFECT; GENE THERAPY; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; REVIEW;

CARDIOTONIC AGENTS; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 2942702060     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13061122     Document Type: Review

References (127)

1. Masiá R, Sala J, Marrugat J, Roure J, Cosín-Aguilar J. The management of heart failure in Spain. Eur J Heart Fail 2000;2:341-4.
2. Cleland J, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6.
3. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31.
4. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ≪malignant≫ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3: 315-22.
5. Levin EL, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
6. Rubattu S, Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens 2001;19:1923-31.
7. Boomsma F, Van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.
8. Nicholls MG. The natriuretic peptides in heart failure. J Intern Med 1994;235:515-26.
9. Dan Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. J Am Coll Cardiol 2001;37:379-85.
10. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal pmatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
11. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
12. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
13. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-901.
14. Marcus LS, Hart D, Packer MM, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
15. Lang CC, Motwani JG, Coutie WJR, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992;82:619-23.
16. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Syhertz E, Frampton CM. Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition. Clin Sci 1997;92:255-60.
17. La Villa G, Riccardi D, Lazzeri C, Casini Raggi V, Dello Sbarba A, Tosti Guerra C, et al. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. Hepatology 1995;22:1745-50.
18. Mills R, Le Jemtel T, Horton D, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62.
19. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
20. Publication Committee for the VMAC investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated heart failure: a randomized controlled trial. JAMA 2002;287: 1531-40.
21. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001:88:35-9.
22. Sagnella GA. Atrial natriuretic peptide mimetics and vasopeptidase inhibitors. Cardiovasc Res 2001;51:416-28.
23. Corti R, Burnett J, Rouleau J, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors. A new therapeutic concept in cardiovascular disease? Circulation 2001;104:1856-62.
24. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356: 615-20.
25. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6.
26. Coats AJ. Omapatrilat - the story of Overtum and Octave. Int J Cardiol 2002;86:1-4.
27. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-76.
28. Hurlimann D, Enseleit F, Noll G, Luscher TF, Ruschitzka F. Endothelin antagonists and heart failure. Curr Hypertens Rep 2002;4:85-92.
29. Seed A, Love MP, McMurray JJ. Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Failure Rev 2001;6:317-23.
30. Packer M. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: results of the REACH-1 trial [abstract]. Circulation 1998;98(Suppl):1-3.
31. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-207.
32. Tovar JM, Gums JG. Tezosentan in the treatment of acute heart failure. Ann Pharmacother 2002;37:1877-83.
33. O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, et al. Randomized Intravenous TeZosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003,41:1452-7.
34. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;3:243-9.
35. Damas J, Gullestad L, Aukrust P. Cytokines as new treatment targets in chronic heart failure. Curr Control Trials Cardiovasc Med 2001;2:271-7.
36. Feldman, A, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophisiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
37. Herrera EH, Herrera JL, Rodríguez H, Treviño A, Ibarra M, Torre G. Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol 2002; 55:61-6.
38. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 1997;81:627-35.
39. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 1998;97:1375-81.
40. Chung ES, Packer M, Lo KH, Fasamnade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Tberapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
41. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation 2001;103:1083-8.
42. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomized investigation of effects of pentoxyfilline on left ventricular performace in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
43. Gullestadt L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:1102-8.
44. Aukrust P, Damas JK, Gullestad L. Immunomodulating therapy: new treatment modality in congestive heart failure. Congest Heart Fail 2003;9:64-9.
45. Mann DL. Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: has the time come to randomized clinical trials. J Am Coll Cardiol 2001;38:184-6.
46. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9-18.
47. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.
48. Weber KT, Villareal D. Aldosterone and anti-aldosterone therapy in congestive heart failure. Am J Cardiol 1993;71:A3-11.
49. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Cardiac Fail 1996;2:47-54.
50. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Pérez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
51. Zannad F, Bousset B, Alla F. Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001;38:1227-32.
52. Pitt B, Remme W, Zannad F, Neaton J, Martínez F, Roniker B, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
53. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000;35:56-9.
54. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-53.
55. Goldman S, Dyer F, Gómez M, Bennett D, Ticho B, Beckman E, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;106:1348-53.
56. Sabbah HN, Stanley WC, Sharov VG, Mishima T, Tanimura M, Benedict CR, et al. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 2000;102:1990-5.
57. Masson S, Chimenti S, Salio M, Torri M, Limana F, Bernasconi R, et al. CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. Cardiovasc Drug Ther 2001;15:131-8.
58. Turcani M, Rupp H. Modification of left ventricular hypertrophy by chronic etomoxir treatment. Br J Pharmacol 1999; 126:501-7.
59. Bristow M. Etomoxir: a new approach to treatment of chronic heart failure. Lancet 2000;356:1621-2.
60. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000;99:27-35.
61. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999;84:46-50.
62. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 2002;91:278-80.
63. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 2003;9:219-26.
64. Nieminen M, Böhm M, Drexler H, Jondeau G, Filippatos G, Hassin Y, et al. Guidelines for the diagnosis and treatment of acute heart failure [en prensa]. Eur Heart J.
65. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.
66. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
67. Gardner RS, Martin W, Carter R, McDonagh TA. Importance of β-blockade in the treatment of advanced heart failure. Heart 2003;89:1442-4.
68. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 2003;289:712-8.
69. Poole-Wilson PA, Wedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metroprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
70. Cleland JG, Pennel D, Ray S, Murray G, MacFarlane P, Cowley A, et al. The carvedilol hibernation reversible ischaemia trial: marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. Eur J Heart Fail 1999;2:191-6.
71. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
72. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999;83:477-81.
73. Dickstein K, Kjeshus J, for the OPTIMAAL study group. Comparison of the effects of losartan and captopril on mortality in patients following acute myocardial infarction: the OPTIMAAL trial design. Optimal trial in myocardial infarction with the angiotensin II antagonist losartan. Am J Cardiol 1999;83:825-81.
74. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
75. Pfeffer MA, McMurray JJV, Velizquez; EJ, Rouleau JL, Kober L, Maggioni AP, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003;349:1893-906.
76. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
77. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
78. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
79. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
80. The Digitalis Investigation Group (DIG). The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
81. Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic heart failure receiving beta-blockers. Curr Cardiol Rep 2001;3:224-31.
82. Tamargo J, Delpón E. Fisiología del músculo. En: Treguerres J, editor. Fisiología humana. Madrid: Interamericana-McGraw-Hill, 1999; p. 14-35.
83. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995;26(Suppl 1):45-51.
84. Figgit D, Gillies P, Goa K. Levosimendan. Drugs 2001;61:613-27.
85. + sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
86. + channel in rat arterial myocytes. Eur J Pharmacol 1997;333: 249-59.
87. Haserifuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7.
88. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
89. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
90. Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26(Suppl 1):63-9.
91. Nicklas JM, Monsur JC, Bleske BE. Effects of intravenous levosimendan on plasma neurohormpne levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999; 83:I12-5.
92. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
93. Cohn JN, Ferrari R, Sharpe N, on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
94. Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovas Haematol Disord 2003;3:1-30.
95. Lindsay M, Lee R. MMP inhibition as a potential therapeutic strategy for CHF. Drugs News Perspect 2000;13:350-4.
96. Parker M, Lunney E, Ortwine D, Pavlovsky AG, Humblet C, Brouillette CG. Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry. Biochemistry 1999;38:13592-601.
97. Rohde L, Ducharme A, Arroyo L, Aikawa M, Sukhova GH, López-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 15:3063-70.
98. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 2000;46:225-38.
99. Creemers E, CleurJens J, Smits J, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure? Cire Res 2001;89:201-10.
100. Feldman AM, Li YY, McTieman CF. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 2001;357:654-5.
101. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type I (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000;32:109-20.
102. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators of matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med 1999;5: 1135-42.
103. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuated left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
104. Zannad F, Alla F, Dousset B, Pérez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000; 102:2700-6.
105. Hsjjar RJ, Del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000;86:616-21.
106. Frey N, McKinsey TA. Olson EN. Decoding calcium signals involved in cardiac growth and function. Nature Med 2000;6: 1221-7.
107. Houser SR, Piacentino III V, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000;32:1595-607.
108. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000;32:2131-9.
109. Del Monte F, Harding S, Doc W, Gwathmey JK. Hadjar RL Targeting phospholamban by gene transfer in human heart failure. Circulation 2002;105:904-7.
110. Del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2. Circulation 1999; 100:2308-11.
111. Davia & Bernobich E, Ranu HK, Del Monte F, Terracciano CM, MacLeod KT, et al. SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol 2001;33:1005-15.
112. Baartscheer A. Adenovirus gene transfer of SERCA in heart failure. A promising therapeutic approach? Cardiovasc Res 2001; 49:249-52.
113. 2+ ATPase. J Am Coll Cardiol 1999;33(Suppl A):A216.
114. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999;99:641-7.
115. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
116. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenetgic receptor transgenic mice. Proc Natl Acad Sci USA 1999;96:7059-64.
117. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, Anzai T, et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 1999,99:1618-22.
118. Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation indum myocardial proinflammabory cytokine expression. Circulation 2000;101:2338-41.
119. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, et al. Early and delayed consequences of β(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000;101:1707-14.
120. Du X, Autelitano D, Dilley R, Wang B, Dart A. Woodcock E. β2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000;101:71-7.
121. Rockman HA, Chiens KR, Choi D-J, Iaccarino G, Hunter JJ, Ross J Jr, et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998;95: 7000-5.
122. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The eflect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomised controlled study. J Am Coll Cardiol 2001;37:1775-80.
123. Grover GJ, Garlid KD. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 2000;32:677-95.
124. Vasan RS, Benjamin EJ. Diastolic heart failure: no time to relax. N Engl J Mod 2001;344:56-9.
125. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002;105:1503-8.
126. Zile MR, Brutsaert DL. Now concepts in diastolic dysfunction and diastolic how failure. Part I: diagnosis, proposis, and measurements of diastolic function, Circulation 2002;105:1387-93.
127. Cleland JG, Tendera M, Adamus J, Freamantle N, Gray CS, Lye M, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999;1:211-7.